We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01644305
Recruitment Status : Unknown
Verified July 2012 by Ankara Education and Research Hospital.
Recruitment status was:  Active, not recruiting
First Posted : July 19, 2012
Last Update Posted : July 19, 2012
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their association with bone and cardiovascular parameters in patients with Polycystic Ovary Syndrome.

Condition or disease
Polycystic Ovary Syndrome

Study Design

Study Type : Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Polycystic Ovary Syndrome
Idiopathic hirsutism

Outcome Measures

Primary Outcome Measures :
  1. The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Sampling Method:   Probability Sample
Study Population
Hospital Endocrinology Outpatient Clinic

Inclusion Criteria:

  • Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism

Exclusion Criteria:

  • acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs.

any medication known to affect hormonal or metabolic parameters.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01644305

Ankara Education and Research Hospital
Ankara, Turkey, 06340
Sponsors and Collaborators
Ankara Education and Research Hospital
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT01644305     History of Changes
Other Study ID Numbers: 3849
First Posted: July 19, 2012    Key Record Dates
Last Update Posted: July 19, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases